Barclays’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-30,000
| Closed | -$562K | – | 5245 |
|
|
2024
Q1 | $562K | Buy |
30,000
+3,000
| +11% | +$69.2K | ﹤0.01% | 3517 |
|
|
2023
Q4 | $585K | Buy |
+27,000
| New | +$535K | ﹤0.01% | 3783 |
|
|
2020
Q1 | – | Sell |
-28,500
| Closed | -$2.06M | – | 6418 |
|
|
2019
Q4 | $2.06M | Sell |
28,500
-12,400
| -30% | -$1.53M | ﹤0.01% | 2972 |
|
|
2019
Q3 | $5.74M | Sell |
40,900
-27,000
| -40% | -$4.52M | ﹤0.01% | 1730 |
|
|
2019
Q2 | $12.4M | Buy |
67,900
+52,800
| +350% | +$9.01M | 0.01% | 1220 |
|
|
2019
Q1 | $2.4M | Sell |
15,100
-71,800
| -83% | -$10.4M | ﹤0.01% | 2375 |
|
|
2018
Q4 | $8.32M | Buy |
86,900
+75,900
| +690% | +$8.69M | 0.01% | 1263 |
|
|
2018
Q3 | $1.55M | Buy |
11,000
+6,000
| +120% | +$926K | ﹤0.01% | 3175 |
|
|
2018
Q2 | $783K | Buy |
5,000
+1,000
| +25% | +$157K | ﹤0.01% | 3531 |
|
|
2018
Q1 | $644K | Sell |
4,000
-114,800
| -97% | -$19.5M | ﹤0.01% | 3703 |
|
|
2017
Q4 | $19.6M | Buy |
118,800
+60,400
| +103% | +$5.86M | 0.02% | 813 |
|
|
2017
Q3 | $3.64M | Sell |
58,400
-20,200
| -26% | -$1.59M | ﹤0.01% | 1790 |
|
|
2017
Q2 | $6.26M | Buy |
78,600
+76,700
| +4,037% | +$5.54M | 0.01% | 1302 |
|
|
2017
Q1 | $135K | Buy |
+1,900
| New | +$111K | ﹤0.01% | 4659 |
|
|
2016
Q4 | – | Sell |
-57,300
| Closed | -$2.64M | – | 6805 |
|
|
2016
Q3 | $2.64M | Sell |
57,300
-173,700
| -75% | -$7.07M | ﹤0.01% | 1760 |
|
|
2016
Q2 | $6.96M | Buy |
+231,000
| New | +$7.7M | 0.01% | 1079 |
|
|
2015
Q3 | – | Sell |
-5,000
| Closed | -$365K | – | 7011 |
|
|
2015
Q2 | $365K | Buy |
+5,000
| New | +$321K | ﹤0.01% | 3725 |
|
Other funds holding SAGE
IA
HNB
Barclays's SAGE Position: Q3 2025 in Review
Barclays sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 99,618 shares — an estimated $909K sold.
Barclays first reported a position in SAGE in Q4 2014 and held it in 43 quarters. The position peaked at $33.7M in Q4 2017. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Barclays reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Barclays sold 99,618 Sage Therapeutics shares in Q3 2025, an estimated $909K.
- Barclays first reported a position in Sage Therapeutics in Q4 2014 and held it in 43 quarters.
- Barclays's Sage Therapeutics position peaked at $33.7M in Q4 2017.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.